Pathological Research Services for Diabetic Cardiovascular Complications
Ace Therapeutics leverages advanced experimental platforms and expertise to provide systematic pathological mechanism research services. We employ key molecular screening, combined molecular pathology techniques, target detection, immunofluorescence in situ hybridization (FISH), and multi-omics analysis to deeply elucidate the pathological mechanisms of diabetic cardiovascular complications. Our multi-layered experimental strategies are designed to help clients decode disease mechanisms and identify key targets and biomarkers, thus significantly enhancing the scientific basis of R&D decision-making and accelerating the development of effective therapies.
Overview of Pathological Research Services for Diabetic Cardiovascular Complications
Diabetes accelerates macrovascular and microvascular complications through multiple pathways involving hyperglycemia, insulin resistance, and chronic inflammation, significantly increasing the risk of coronary heart disease, heart failure, and cerebrovascular events. Classic mechanisms include activation of the polyol pathway, accumulation of advanced glycation end products (AGEs), activation of protein kinase C, and oxidative stress. These factors collectively drive endothelial dysfunction, abnormal smooth muscle proliferation, and fibrotic remodeling.
Fig. 1 Pathology and molecular mechanisms of diabetic heart disease. (Li, Yiwen, et al., 2023)
Key challenges in diabetic cardiovascular disease mechanism research include the following:
- Complex interplay of multiple mechanisms: Pathways involving metabolism, inflammation, and oxidative stress exhibit significant crosstalk, making it difficult for single-target approaches to fully elucidate disease progression.
- Lack of effective models: Traditional animal models struggle to replicate the progressive nature of human diseases and lack integrated systems for simultaneously evaluating metabolic and cardiovascular phenotypes.
- Translational gap: A disconnect between molecular mechanism research and efficacy assessment hinders target validation from effectively informing downstream drug development decisions.
Our Pathological Research Services for Diabetic Cardiovascular Complications
Ace Therapeutics provides professional services spanning target discovery, mechanism validation, and model verification to support clients in identifying novel targets for diabetic cardiovascular complications.
Pathogenesis Research and Target Discovery Services
- Key pathway research: Focusing on the activation status and regulatory networks of core pathways including oxidative stress (Nrf2/HO-1), inflammation (NF-κB, TGF-β), metabolic remodeling (AMPK/mTOR), and endothelial function (eNOS/NO).
- Cell-cell interaction mechanisms: Elucidating paracrine/autocrine regulatory mechanisms between cardiomyocyte-fibroblast, endothelial-smooth muscle, and immune-vascular cell interactions.
Custom Diabetic Cardiovascular Complications Modeling and Mechanism Validation Services
- Customized disease modeling: We provide models including STZ combined with high-fat diet induction, db/db mice (obese diabetes), and ZDF rats (type 2 diabetes), simulating the pathological features of cardiovascular complications in different types of diabetes.
- Mechanism-driven model validation: We employ techniques including gene knockout/overexpression and inhibitor interventions in our models to confirm the role of candidate targets in the development of diabetic cardiovascular complications.
- Humanized model applications: Utilizing iPSC-derived cardiomyocytes and vascular endothelial cells to establish in vitro models that recapitulate the disease microenvironment.
Biomarker Discovery and Validation Services
- Multi-omics screening: Through transcriptomics, proteomics, and metabolomics analysis, identify specific molecular biomarkers for diabetic cardiovascular complications (e.g., myocardial injury markers, inflammatory cytokines, metabolites).
- Functional validation: Verifying biomarker correlations with disease progression (e.g., myocardial fibrosis extent, vascular plaque stability) in cellular/animal models.
- Biological sample collection and analysis: We collect and analyze biological samples (e.g., blood, tissue) from our diabetic animal models, providing clients with a multidimensional data package that correlates biochemical, molecular, and cellular findings with histopathological endpoints.
Technology Platform at Ace Therapeutics
We integrate cutting-edge technologies to provide a precision research platform for studying the mechanisms of cardiovascular complications in diabetes.
| Platform |
Core Technology |
Applications |
| Molecular Biology Platform |
Western blot, qPCR, ChIP-seq |
Quantification of signaling proteins (e.g., NF-κB, p-AMPK), gene expression profiling, and genome-wide analysis of transcriptional regulation (via ChIP-seq). |
| Imaging Platform |
High-resolution echocardiography, confocal microscopy, and magnetic resonance imaging (MRI) |
Non-invasive evaluation of cardiac structure/function (echocardiography, MRI), high-resolution cellular and tissue imaging (confocal microscopy). |
| Multi-omics Platform |
Transcriptome (RNA-seq), Metabolome (LC-MS) |
Unbiased discovery of differentially expressed genes and dysregulated metabolic pathways. |
| Functional Testing Platform |
Wire myograph, cardiomyocyte contractility analyzer |
Ex vivo assessment of vascular reactivity (wire myograph) and cardiomyocyte contractility. |
| In Vitro Model Platform |
iPSC differentiation Systems, 3D organoid culture |
Human-relevant mechanistic studies using iPSC-derived cardiomyocytes and 3D vascular organoids. |
Ace Therapeutics partners with clients worldwide to conduct in-depth mechanistic research on diabetic cardiovascular complications. We provide end-to-end technical services, ranging from key molecule screening and target functional validation to live-cell dynamic imaging, multi-omics integration, and tissue microarray validation. Contact us today for customized research proposals and quotes.
References
- Li, Yiwen, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal transduction and targeted therapy. 8.1 (2023): 152.
- Wu, H., et al. Diabetes and Its Cardiovascular Complications: Comprehensive Network and Systematic Analyses. Front Cardiovasc Med. 2022; 9: 841928.
All of our services and
products are intended for preclinical research use only and cannot be used to diagnose, treat or
manage patients.
Related Services
Related Products
